Compare Citius Pharmaceuticals Inc (CTXR) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs US Bancorp — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while US Bancorp trades at $64.49 (market cap $100.17B). The key difference: US Bancorp is far larger — about 5006× Citius Pharmaceuticals Inc's market cap, and US Bancorp pays a 3.24% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | USB | |
|---|---|---|
Market Cap | $20.01M | $100.17B |
Sector | Health | Financials |
52-Week High | $1.82 | $64.47 |
52-Week Low | $0.48 | $45.28 |
Enterprise Value | $16.23M | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
U.S. Bancorp (USB) trades at $64.19, up 0.39% today, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.35 surpassing the $1.28 expectation. Revenue and net income have shown steady growth, with 2025 revenue at $28.54 billion and net income at $7.57 billion. Analyst sentiment is positive, with a consensus price target of $70.27, indicating potential upside.
The outlook for USB is favorable, supported by robust earnings growth, a solid dividend, and positive analyst ratings. Key risks include exposure to interest rate fluctuations and macroeconomic volatility, as highlighted by recent news on potential Fed rate hikes. Institutional investors have been increasing stakes, reinforcing confidence. The stock presents a compelling opportunity for value-oriented investors seeking steady returns amid a stable banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
